What is a Digital Twin in Medical Device Context?

In medical device development, a digital twin is a computational model — typically finite element analysis (FEA), computational fluid dynamics (CFD), or multibody simulation — that replicates the physical device's mechanical, thermal, or fluid behaviour under simulated conditions. A digital twin can be used to: simulate device performance across a range of use scenarios without physical prototyping, predict mechanical failure modes, optimise geometry and material selection, simulate patient-specific loading conditions for implants, and generate virtual evidence for regulatory submissions. The 'twin' becomes more valuable when it is validated against physical test data — demonstrating that simulation predictions match measured results within defined tolerance.

FDA's Acceptance of Computational Modelling Evidence

The FDA published the landmark guidance 'Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions' (2021) and the broader 'Framework for Computational Modeling and Simulation to Support Device Submissions' — establishing that well-validated computational models can contribute to regulatory evidence in 510(k) and PMA submissions. The key concept is model credibility: demonstrating through verification, validation, and uncertainty quantification (VVUQ) that the simulation is sufficiently accurate for its intended use. This does not mean replacing physical testing — rather, computational evidence supplements physical testing for parameter ranges and use scenarios that would be impractical or unethical to test physically.

EU MDR and In Silico Methods

The European Commission's MDCG is actively developing guidance on in silico methods (computational simulation) under EU MDR, with several technical groups working on digital twin frameworks for specific device categories (cardiovascular implants, orthopaedic implants, dental devices). ISO 10993-1:2025 references in silico methods as alternatives to some in vivo biocompatibility tests. While the EU regulatory framework for computational evidence is less explicitly defined than the FDA's, Notified Bodies are increasingly accepting well-documented FEA evidence as supplementary support for mechanical testing claims in Class IIb and III technical files.

Orthopaedic and Cardiovascular Applications

The two most mature medical device digital twin application areas are: (1) Orthopaedic implants — FEA is used to simulate implant fatigue life, bone-implant stress distribution, and fixation stability across patient anatomical variability; this evidence is well-established in regulatory submissions for hip, knee, and spine implants. (2) Cardiovascular devices — CFD simulation of blood flow through stents, heart valves, and vascular grafts is used to assess thrombogenicity risk, haemodynamic performance, and device sizing; FDA guidance on cardiovascular device computational modelling is the most developed of any device category. Turkish orthopaedic and cardiovascular device manufacturers are the most immediately positioned to benefit from digital twin adoption.

Digital Twins in Manufacturing Process Validation

Beyond product design, digital twins have a growing role in manufacturing process simulation. A manufacturing digital twin can model the production line, identify bottlenecks, simulate the effect of parameter changes on product quality, and support process validation documentation. For Turkish medical device manufacturers investing in new production lines or processes — including additive manufacturing — digital twins of manufacturing processes can reduce physical validation runs, accelerate process development, and strengthen process validation documentation for regulatory submissions.

Practical Steps for Turkish Manufacturers

Turkish manufacturers considering digital twin adoption should: (1) Identify the specific device category and design question where simulation would have the most value — start focused, not broad, (2) Assess internal engineering capability: FEA and CFD simulation requires specialised engineering skills; consider whether to build in-house capability or partner with a specialist simulation consultancy, (3) Validate any simulation model against physical test data before using it in regulatory submissions — model credibility is the regulatory requirement, not simulation capability alone, (4) Engage your Notified Body or FDA reviewer early to understand their specific expectations for computational evidence in your device category.

Conclusion

Digital twins are transitioning from a cutting-edge innovation to a practical design and regulatory tool for forward-thinking medical device manufacturers. Turkish manufacturers who invest in validated computational modelling capability — even for specific, high-value applications — will gain design speed advantages, reduce physical testing costs, and build regulatory evidence portfolios that give their products a differentiated position in technical file reviews and clinical buyer evaluations.